OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results 
Apple Tests China's CXMT Memory Chips as DRAM Maker Gains Global Market Share 
Telenor to Buy Controlling Stake in Bahnhof in $630 Million Broadband Deal 
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 
Goldman AM Sees Strong Buyout Opportunities in Japan, South Korea and Australia 
SK Hynix’s $28 Billion U.S. Share Sale Draws Massive Demand Amid AI Chip Boom 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
Netflix, Disney, YouTube Eye FIFA World Cup TV Rights in Multi-Billion Dollar Battle 
Bernstein Names IAG, Ryanair as Top European Airline Stocks Ahead of Earnings 
OpenAI GPT-5.6 Set for Wider Release After U.S. Commerce Approval, Report Says 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Nvidia Invests $500M in Firmus Technologies Ahead of Planned ASX IPO 
Mizuho’s Top U.S. Industrials Stocks: Why Corteva and Stanley Black & Decker Stand Out 
Japan Regional Bank Stocks Drop After Zentoshin Bankruptcy Sparks Credit Risk Concerns 
Lockheed Martin, Rheinmetall Plan First ATACMS Missile Production in Germany 
BETHLEHEM, Pa., May 03, 2018 -- B. Braun Medical Inc., an industry pioneer in offering products not made with DEHP and PVC, will showcase its portfolio of solution containers at the CleanMed 2018 Conference & Exposition on May 7-9 at the Sheraton San Diego Hotel and Marina in booth #203.
Di-ethylhexyl Phthalate (DEHP) and Polyvinyl Chloride (PVC) are potentially toxic to patients and the environment – and they’re commonly used in IV bags, tubing, and packaging.
“B. Braun has been at the forefront of recognizing the patient and environmental risk posed by exposure to products containing DEHP and PVC. We were one of the first IV fluid manufacturers to remove these toxic substances from many of our products and proudly remain the only supplier that offers a full-line of IV solution containers that are not made with DEHP and PVC,” said Tom Sutton, Vice President of Marketing, Medical Device and Pharmaceutical Systems.
Over the past seven years, B. Braun has invested more than $750 million in developing increased capacity, and innovative ways to offer environmentally friendly IV solutions. This includes new product lines not made with DEHP, PVC, or natural rubber latex. B. Braun actively supports policies calling for the industry-wide reduction of these chemicals and natural rubber latex in medical devices.
For more information on these products, call B. Braun Clinical and Technical Support at 800-854-6851. For more information on DEHP and PVC in healthcare, visit www.BBraunCares.com.
About B. Braun
B. Braun Medical Inc., a leader in infusion therapy and pain management, develops, manufactures, and markets innovative medical products and services to the healthcare industry. Other key product areas include ostomy and wound care, dialysis, nutrition, pharmacy admixture and compounding. The company is committed to eliminating preventable treatment errors and enhancing patient, clinician and environmental safety. B. Braun Medical is headquartered in Bethlehem, Pa., and is part of the B. Braun Group of Companies in the U.S., which includes B. Braun Interventional Systems, Aesculap® and CAPS®.
Globally, the B. Braun Group of Companies employs more than 61,000 employees in 64 countries. Guided by its Sharing Expertise® philosophy, B. Braun continuously exchanges knowledge with customers, partners and clinicians to address the critical issues of improving care and lowering costs. To learn more about B. Braun Medical, visit www.BBraunUSA.com.
Contact: Jason Ford
B. Braun Medical Inc.
610.997.4722
[email protected]
